JATT II Acquisition Corp. Announces Definitive Business Combination with Talawar Tx Inc. and $225M PIPE
JATT is trading near its 52-week low of $10 (14% above the low) on elevated volume (2.4× avg).
Summary
JATT II Acquisition Corp. announced a definitive business combination with biotech firm Talawar Tx Inc., which will go public with a $120.0 million pre-money valuation and secure $225.0 million in PIPE financing, providing critical capital to advance its lead drug candidate.
Key Events · M&A and Partnerships · JATT
-
Definitive Business Combination Agreement
JATT II Acquisition Corp. has entered into a definitive business combination agreement with Talawar Tx Inc., a biotechnology company, to create a publicly listed entity named Talawar Therapeutics (TLWR).
-
Implied Valuation
Talawar Tx Inc. is valued at an implied pre-money equity value of $120.0 million in the transaction.
-
Substantial PIPE Financing
The transaction includes a $225.0 million concurrent private investment in public equity (PIPE) at $10.00 per share, led by major healthcare-dedicated investors.
-
Significant Capital Infusion
The combined company is anticipated to receive $285.0 million in available cash at closing (assuming no redemptions), which is expected to fund the lead program TALA-125 through a Phase 2b data readout in 2H 2028.
Analysis · JATT · Real Estate & Construction
This filing details the definitive business combination agreement between JATT II Acquisition Corp. (a SPAC) and Talawar Tx Inc., a biotechnology company. The transaction will bring Talawar Tx public, with the combined entity expected to trade under the ticker TLWR on Nasdaq. A substantial $225.0 million PIPE financing, priced at $10.00 per share and backed by prominent healthcare investors, is a key component of the deal. This, combined with JATT's trust account (assuming no redemptions), is anticipated to provide $285.0 million in available cash, which is crucial for funding Talawar's lead bispecific antibody program, TALA-125, through a Phase 2b data readout in the second half of 2028. While the transaction results in significant dilution for existing JATT public shareholders, it provides the necessary capital and a clear path for the combined biotech company's development, signaling strong institutional confidence.
At the time of this filing, JATT was trading at $11.38 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $91.3M. The 52-week trading range was $10.00 to $12.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.